NCT00232141

Study of Pregabalin Versus Placebo in the Treatment of Nerve Pain Associated With HIV Neuropathy

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center Trial of Pregabalin Versus Placebo in the Treatment of Neuropathic Pain Associated With HIV Neuropathy.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 302 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study to determine if pregabalin is more effective than placebo in treating subjects with nerve pain associated with HIV neuropathy.

Conditions

• HIV Infections
• Peripheral Neuropathy

Interventions

Type	Name	Description
DRUG	pregabalin	75mg BID (can be titrated up to 150mg BID on day 4 based on individual response and up to 300mg BID at the end of week 1, visit 3 and end of week 2, visit 4)
DRUG	Placebo	Placebo

Timeline

• Start date: 2005-10-01
• Primary completion: 2007-11-01
• Completion: 2007-11-01
• First posted: 2005-10-04
• Last updated: 2021-02-09
• Results posted: 2009-08-11

Locations

44 sites across 2 countries: United States, Puerto Rico